Design Therapeutics, Inc. $DSGN Shares Purchased by Sei Investments Co.

Key Points

• Sei Investments increased its Design Therapeutics stake by 152.6% in the first quarter, reaching 133,203 shares valued at approximately $1.42 million. Institutional investors collectively own 56.64% of DSGN.
• Analyst sentiment remains broadly positive, with a consensus rating of “Moderate Buy” and an average price target of $16.50. Ratings include six Buys, one Strong Buy, and one Sell.
• DSGN recently traded at $14.33, up 2.4%, and reported quarterly EPS of negative $0.32—beating consensus estimates of negative $0.34. Analysts expect a full-year loss of approximately $1.41 per share.

Sei Investments Co. raised its holdings in Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 152.6% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 133,203 shares of the company's stock after acquiring an additional 80,473 shares during the quarter. Sei Investments Co. owned 0.21% of Design Therapeutics worth $1,417,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in the business. Elmind Capital LP bought a new stake in shares of Design Therapeutics in the 4th quarter worth approximately $1,950,000. Baker BROS. Advisors LP increased its holdings in shares of Design Therapeutics by 30.4% in the fourth quarter. Baker BROS. Advisors LP now owns 2,233,099 shares of the company's stock valued at $20,946,000 after buying an additional 520,217 shares in the last quarter. 9823 Capital L.P. acquired a new stake in shares of Design Therapeutics during the 4th quarter valued at $180,000. AXQ Capital LP acquired a new stake in shares of Design Therapeutics during the 4th quarter valued at $110,000. Finally, Strs Ohio boosted its stake in shares of Design Therapeutics by 11.5% during the 4th quarter. Strs Ohio now owns 25,200 shares of the company's stock worth $236,000 after acquiring an additional 2,600 shares in the last quarter. Institutional investors own 56.64% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on DSGN shares. Weiss Ratings restated a "sell (d-)" rating on shares of Design Therapeutics in a report on Friday, July 17th. Cantor Fitzgerald began coverage on Design Therapeutics in a research report on Tuesday, May 12th. They issued an "overweight" rating for the company. Wall Street Zen raised Design Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday, May 10th. Piper Sandler restated an "overweight" rating and set a $20.00 price objective on shares of Design Therapeutics in a report on Wednesday, April 29th. Finally, Oppenheimer upped their price objective on shares of Design Therapeutics from $18.00 to $21.00 and gave the company an "outperform" rating in a research note on Monday, May 4th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $16.50.

Design Therapeutics Trading Up 2.4%

NASDAQ:DSGN opened at $14.33 on Tuesday. The firm has a market capitalization of $896.77 million, a price-to-earnings ratio of -12.14 and a beta of 1.63. Design Therapeutics, Inc. has a 1-year low of $4.23 and a 1-year high of $17.25. The business's fifty day moving average price is $12.79 and its 200 day moving average price is $11.87.

Design Therapeutics (NASDAQ:DSGN - Get Free Report) last announced its quarterly earnings data on Monday, August 3rd. The company reported ($0.32) EPS for the quarter, topping analysts' consensus estimates of ($0.34) by $0.02. Equities analysts forecast that Design Therapeutics, Inc. will post -1.41 earnings per share for the current year.

Design Therapeutics Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders.

Want to see what other hedge funds are holding DSGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source